Cargando…

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production

Nafamostat mesilate (NM) is a serine protease inhibitor with anticoagulant and anti-inflammatory effects. NM has been used in Asia for anticoagulation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation. Oxidative str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Min-Woong, Song, Hee-Jung, Kang, Shin Kwang, Kim, Yonghwan, Jung, Saet-byel, Jee, Sungju, Moon, Jae Young, Suh, Kwang-sun, Lee, Sang Do, Jeon, Byeong Hwa, Kim, Cuk-Seong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Physiological Society and The Korean Society of Pharmacology 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422962/ https://www.ncbi.nlm.nih.gov/pubmed/25954127 http://dx.doi.org/10.4196/kjpp.2015.19.3.229

Ejemplares similares

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation
por: Han, Sang Jin, et al.
Publicado: (2011)

Rg3-enriched Korean Red Ginseng enhances blood pressure stability in spontaneously hypertensive rats
por: Nagar, Harsha, et al.
Publicado: (2016)

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

CRIF1 Deficiency Induces p66shc-Mediated Oxidative Stress and Endothelial Activation
por: Nagar, Harsha, et al.
Publicado: (2014)

Rg3-enriched Korean Red Ginseng improves vascular function in spontaneously hypertensive rats
por: Park, Jung-Bum, et al.
Publicado: (2014)

Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
por: Takada, Naoki, et al.
Publicado: (2021)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Secreted APE1/Ref-1 inhibits TNF-α-stimulated endothelial inflammation via thiol-disulfide exchange in TNF receptor
por: Park, Myoung Soo, et al.
Publicado: (2016)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study
por: Lee, Yong Kyu, et al.
Publicado: (2014)

Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
por: Haruki, Koichiro, et al.
Publicado: (2017)

The 18-kDa Translocator Protein Inhibits Vascular Cell Adhesion Molecule-1 Expression via Inhibition of Mitochondrial Reactive Oxygen Species
por: Joo, Hee Kyoung, et al.
Publicado: (2015)

Inhibition of intimal hyperplasia by local perivascular application of rapamycin and imatinib mesilate after carotid balloon injury
por: Park, Daedo, et al.
Publicado: (2013)

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials
por: Xie, Yu, et al.
Publicado: (2023)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

The tumor suppressive effect and apoptotic mechanism of TRAIL gene‐containing recombinant NDV in TRAIL‐resistant colorectal cancer HT‐29 cells and TRAIL‐nonresistant HCT116 cells, with each cell bearing a mouse model
por: Jung, Bo‐Kyoung, et al.
Publicado: (2023)

Redox Factor-1 Activates Endothelial SIRTUIN1 through Reduction of Conserved Cysteine Sulfhydryls in Its Deacetylase Domain
por: Jung, Saet-Byel, et al.
Publicado: (2013)

Predicting the systemic exposure and lung concentration of nafamostat using physiologically-based pharmacokinetic modeling
por: Jeong, Hyeon-Cheol, et al.
Publicado: (2022)

Correction: Hiroshi Sugano et al. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers 2018, 10, 386
por: Sugano, Hiroshi, et al.
Publicado: (2019)

Antitumor Potential of Sericite Treatment Mediated by Cell Cycle Arrest in Triple-Negative MDA-MB231 Breast Cancer Cells
por: Kim, Seonhee, et al.
Publicado: (2022)

Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial
por: Hirota, Morihisa, et al.
Publicado: (2019)

SIRT1 deacetylates APE1 and regulates cellular base excision repair
por: Yamamori, Tohru, et al.
Publicado: (2010)

Mechanisms of NMDA Receptor Inhibition by Sepimostat—Comparison with Nafamostat and Diarylamidine Compounds
por: Zhigulin, Arseniy S., et al.
Publicado: (2023)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Trichostatin A Modulates Angiotensin II-induced Vasoconstriction and Blood Pressure Via Inhibition of p66shc Activation
por: Kang, Gun, et al.
Publicado: (2015)

In Vivo Neuroprotective Effect of Histidine-Tryptophan-Ketoglutarate Solution in an Ischemia/Reperfusion Spinal Cord Injury Animal Model
por: Kang, Shin Kwang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1l8tq4tp2jcunhedemq8o4f1g1